# Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery

> **NCT01127581** · PHASE3 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 1358 (actual)

## Conditions studied

- Reducing Time to Vaginal Delivery
- Cervical Ripening
- Induction of Labor

## Interventions

- **DRUG:** MVI 200
- **DRUG:** Dinoprostone Vaginal Insert (DVI)

## Key facts

- **NCT ID:** NCT01127581
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 1358 (ACTUAL)
- **Last updated:** 2014-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01127581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01127581, "Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01127581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*